A major US trial adds weight to the argument that HPV DNA testing should be the primary screening tool for cervical cancer and shows genotyping could be used to effectively triage HPV positive women.
HPV testing alone had a sensitivity of 92% for the detection of cervical intraepithelial neoplasia grade 3 (CIN3) or worse, compared with 53% for liquid-based cytology, the ATHENA trial of over 40,000 screened women found.
Consistent with previous studies, HPV testing had poorer specificity (57%), compared with liquid based cytology (73%).
Importantly, for women infected with HPV, HPV16 and HPV18 genotyping alone was as good as cytology for detecting cervical intraepithelial neoplasia grade 3 (CIN3) or worse, the study found.
Additionally, the performance of HPV16 and HPV18 genotyping was much...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.